

Special Issue

Novel Therapeutic Approaches for Cancer Treatment

Message from the Guest Editor

Cancer affects a significant proportion of the global population and, according to the World Health Organization (WHO), is the second cause of death worldwide. Genetic and epigenetic alterations are among the most critical factors in the onset of carcinomas. Conventional treatment approaches, such as surgery, chemotherapy and radiotherapy, are still in use, while significant advances are being made in various fields, including stem cell therapy, targeted therapy, ablation therapy, nanoparticles, natural antioxidants, photodynamic therapy, sonodynamic therapy, immunotherapy and ferroptosis-based therapy. This Special Issue aims at collecting original research articles and comprehensive reviews on the most recent advances concerning cancer treatment, such as, but not limited to, novel small anticancer molecules, epigenetic drugs, nanotechnology-based combination therapies, targeted therapies including external stimuli-activated approaches, drug repurposing and immunotherapeutic.

Guest Editor

Prof. Dr. Marzia Bruna Gariboldi

Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy

Deadline for manuscript submissions

30 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/197754

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)